Skip to main content
. 2023 Jan 25;24(3):2398. doi: 10.3390/ijms24032398

Figure 2.

Figure 2

Cell proliferation in pATC cells. WST-1 assay in pATC cells with (A) or without (B) V600EBRAF mutation, treated with pazopanib (1, 10, 25, or 50 µM) for 24 h. The pATC cell proliferation was significantly reduced vs. control (Ctrl). The obtained results were similar in tumors in presence/absence of the V600EBRAF mutation. Bars represent the mean ± SD. * p < 0.05 vs. control according to Bonferroni–Dunn test.